NO20090797L - Farmasoytiske blandinger omfattende kandesartan cileksetil - Google Patents
Farmasoytiske blandinger omfattende kandesartan cileksetilInfo
- Publication number
- NO20090797L NO20090797L NO20090797A NO20090797A NO20090797L NO 20090797 L NO20090797 L NO 20090797L NO 20090797 A NO20090797 A NO 20090797A NO 20090797 A NO20090797 A NO 20090797A NO 20090797 L NO20090797 L NO 20090797L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical compositions
- candesartan cilexetil
- candesartan
- cilexetil
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Farmasøytisk preparat omfattende som en aktiv bestanddel kandesartan eller kandesartan cileksetil, preparat som har en relativ biotilgjengelighet målt som arealet under kurven, på mer enn 1,5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84243206P | 2006-09-05 | 2006-09-05 | |
PCT/SE2007/000771 WO2008030161A1 (en) | 2006-09-05 | 2007-09-04 | Pharmaceutical composition comprising candesartan cilexetil |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20090797L true NO20090797L (no) | 2009-03-19 |
Family
ID=39157499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20090797A NO20090797L (no) | 2006-09-05 | 2009-02-20 | Farmasoytiske blandinger omfattende kandesartan cileksetil |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080058399A1 (no) |
EP (1) | EP2063888A4 (no) |
JP (1) | JP2010502698A (no) |
KR (1) | KR20090049089A (no) |
CN (1) | CN101528224A (no) |
AU (1) | AU2007293727A1 (no) |
BR (1) | BRPI0716445A2 (no) |
CA (1) | CA2662040A1 (no) |
IL (1) | IL197093A0 (no) |
MX (1) | MX2009002425A (no) |
NO (1) | NO20090797L (no) |
WO (1) | WO2008030161A1 (no) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1965795A2 (en) * | 2005-12-29 | 2008-09-10 | Teva Pharmaceutical Industries Ltd. | Metaxalone formulations and methods for the preparation thereof |
RU2009141539A (ru) * | 2007-04-25 | 2011-05-27 | Тева Фармасьютикал Индастриес Лтд. (Il) | Комплекс фармацевтического наполнителя |
EP2182927A2 (en) * | 2007-08-01 | 2010-05-12 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of candesartan |
DE102007052070A1 (de) | 2007-10-30 | 2009-05-07 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Candesartancilexetil |
EP2106789A1 (en) * | 2008-03-31 | 2009-10-07 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising candesartan |
CN101862325B (zh) * | 2009-04-20 | 2013-12-04 | 北京德众万全药物技术开发有限公司 | 一种含有坎地沙坦酯的药物组合物 |
HUP0900384A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate olmesartan medoxomil compositions |
HUP0900376A2 (en) * | 2009-06-19 | 2011-01-28 | Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag | Nanoparticulate candesartan cilexetil composition |
CZ302789B6 (cs) * | 2009-11-25 | 2011-11-09 | Zentiva, K. S. | Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva |
WO2011109579A1 (en) * | 2010-03-04 | 2011-09-09 | Theravance, Inc. | Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof |
JP2012051829A (ja) * | 2010-08-31 | 2012-03-15 | Taiyo Yakuhin Kogyo Kk | 安定なアンジオテンシii受容体拮抗作用を示す薬物製剤の設計 |
JP5756651B2 (ja) * | 2011-02-24 | 2015-07-29 | エルメッド エーザイ株式会社 | カンデサルタンシレキセチルを安定化した組成物及びその製造方法 |
JP2013067574A (ja) * | 2011-09-21 | 2013-04-18 | Teva Pharma Japan Inc | 安定化された医薬組成物 |
WO2014010008A1 (ja) * | 2012-07-09 | 2014-01-16 | 東洋カプセル株式会社 | カンデサルタンシレキセチルのカプセル充填用組成物 |
CN102885810B (zh) * | 2012-10-30 | 2015-08-05 | 台州职业技术学院 | 一种坎地沙坦酯双释胶囊及其制备方法 |
EP2952187A4 (en) | 2013-01-30 | 2016-08-17 | Sawai Seiyaku Kk | PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL |
KR101710441B1 (ko) * | 2015-12-28 | 2017-02-28 | 신풍제약주식회사 | 안정성 및 용출성이 향상된 정제 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9912145A (pt) * | 1998-07-20 | 2001-09-25 | Smithkline Beecham Corp | Formulações bioaperfeiçoadas contendo eprosartan em forma de dosagem sólida oral |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
WO2002030400A1 (fr) * | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
WO2005070398A2 (en) * | 2004-01-23 | 2005-08-04 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
WO2005079751A2 (en) * | 2004-01-23 | 2005-09-01 | Ranbaxy Laboratories Limited | Oral pharmaceutical compositions of candesartan cilexetil |
EP1713795A2 (en) * | 2004-02-11 | 2006-10-25 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
WO2005123721A2 (en) * | 2004-06-18 | 2005-12-29 | Ranbaxy Laboratories Limited | Amorphous and polymorphic forms of candesartan cilexetil |
EP1655298A1 (en) * | 2004-11-03 | 2006-05-10 | LEK Pharmaceuticals d.d. | Novel polymorph forms of candesartan cilexetil |
US20060099230A1 (en) * | 2004-11-10 | 2006-05-11 | Chin-Chih Chiang | Novel formulations of eprosartan with enhanced bioavailability |
US20060111417A1 (en) * | 2004-11-23 | 2006-05-25 | Purandhar Koilkonda | Amorphous telmisartan |
BRPI0606434A2 (pt) * | 2005-01-06 | 2009-06-30 | Elan Pharma Int Ltd | formulações de candesartana nanoparticulada |
KR20080042039A (ko) * | 2005-04-18 | 2008-05-14 | 루비콘 리서치 피브이티. 엘티디. | 생물학적으로 강화된 조성물 |
-
2007
- 2007-09-04 JP JP2009527320A patent/JP2010502698A/ja active Pending
- 2007-09-04 CN CNA2007800328122A patent/CN101528224A/zh active Pending
- 2007-09-04 BR BRPI0716445-9A2A patent/BRPI0716445A2/pt not_active IP Right Cessation
- 2007-09-04 AU AU2007293727A patent/AU2007293727A1/en not_active Abandoned
- 2007-09-04 EP EP07808791A patent/EP2063888A4/en not_active Withdrawn
- 2007-09-04 MX MX2009002425A patent/MX2009002425A/es not_active Application Discontinuation
- 2007-09-04 WO PCT/SE2007/000771 patent/WO2008030161A1/en active Application Filing
- 2007-09-04 CA CA002662040A patent/CA2662040A1/en not_active Abandoned
- 2007-09-04 KR KR1020097006712A patent/KR20090049089A/ko not_active Application Discontinuation
- 2007-09-05 US US11/850,049 patent/US20080058399A1/en not_active Abandoned
-
2009
- 2009-02-17 IL IL197093A patent/IL197093A0/en unknown
- 2009-02-20 NO NO20090797A patent/NO20090797L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2009002425A (es) | 2009-03-20 |
IL197093A0 (en) | 2009-11-18 |
CA2662040A1 (en) | 2008-03-13 |
WO2008030161A1 (en) | 2008-03-13 |
KR20090049089A (ko) | 2009-05-15 |
CN101528224A (zh) | 2009-09-09 |
EP2063888A1 (en) | 2009-06-03 |
US20080058399A1 (en) | 2008-03-06 |
BRPI0716445A2 (pt) | 2013-09-17 |
EP2063888A4 (en) | 2009-11-04 |
JP2010502698A (ja) | 2010-01-28 |
AU2007293727A1 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20090797L (no) | Farmasoytiske blandinger omfattende kandesartan cileksetil | |
NO20091395L (no) | Nye tiofenderivater | |
NO20083462L (no) | Nye tiofenderivater som S1P1/EDG1-reseptoragonister | |
NO20075298L (no) | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | |
NO20082793L (no) | Nye tiofenderivater | |
BRPI0720972B8 (pt) | compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos | |
DK3984528T3 (da) | Farmaceutiske sammensætninger, som omfatter nilotinib | |
NO20093146L (no) | Amino-pyridinderivater som S1P1/EDG1-reseptoragonister | |
WO2009156462A3 (en) | Organic compounds | |
WO2010056022A3 (en) | Melanocortin receptor agonists | |
WO2008051942A3 (en) | Farnesoid x receptor agonists | |
WO2010012442A3 (en) | Insecticidal benzenedicarboxamide derivative | |
CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
NI201000172A (es) | Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad. | |
CL2007001919A1 (es) | Compuestos derivados de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; composicion farmaceutica que comprende a dichos compuestos, utiles como anticonceptivos. | |
EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
CL2009000904A1 (es) | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. | |
WO2008154234A3 (en) | Extended release formulation of nevirapine | |
WO2009038412A3 (en) | Beta-secretase inhibiting compounds | |
BR112012024428A2 (pt) | composição farmacêutica de dissolução rápida | |
CL2007002812A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica, utiles para inhibir el vih. | |
CY1109865T1 (el) | Συνθεσεις βαλσαρτανης | |
ECSP10010683A (es) | Una formulacion farmacéutica sólida | |
WO2011014003A3 (en) | (+)-3-hydroxymorphinan derivatives as neuroprotectants | |
EA201001125A1 (ru) | Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |